HPV 6/11, 16, 18 Seroprevalence in Men in Two US Cities

Dunne, Eileen F. MD*; Nielson, Carrie M. PHD†‡; Hagensee, Michael E. MD§; Papenfuss, Mary R. MPH¶; Harris, Robin B. PHD‡; Herrel, Nicholas BS§; Gourlie, Jennifer BS§; Abrahamsen, Martha MPH¶; Markowitz, Lauri E. MD*; Giuliano, Anna R. PHD¶

doi: 10.1097/OLQ.0b013e3181bc094b
Articles

Background: A vaccine to prevent human papillomavirus (HPV) 6, HPV 11, HPV 16, or HPV 18 and associated diseases is licensed for females, and it may be licensed for men in the future. There are limited data on HPV 6/11, 16, and/or 18 seroprevalence in men.

Methods: A total of 490 men aged 18 to 40 years were enrolled in a study of HPV in men in Tucson, AZ, and Tampa, FL. Enrolled men completed a self-administered questionnaire, and HPV serology was performed using HPV 6/11, 16, and 18 VLP assays.

Results: Overall, seroprevalence to HPV 16 was 12.1%, HPV 6/11 was 9.7%, and to HPV 18 was 5.4%. Seroprevalence to HPV 6/11, 16, and/or 18 was 21% and was highest among 35 to 40 year olds (48%); prevalence in this age group was significantly higher compared to the 18 to 24 year olds (adjusted odds ratio (aOR) 6.8, 95% confidence interval (CI) 3.7, 12.8). Independent predictors of seropositivity to HPV 6/11, 16, and/or 18 were older age, greater number of female sex partners in the past 3 months, and current smoking.

Conclusions: HPV vaccine-type seroprevalence was highest in 35 to 40 year old men. These data on the epidemiology of HPV seroprevalence in men are useful for discussions regarding recommendations for HPV vaccine if licensed for use in men.

A study of men in 2 cities in the United States found HPV 6/11, HPV 16, or HPV 18 seroprevalence was associated with older age, number of sex partners, and current smoking.

From the *Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA; †Oregon Health & Science University, Portland, OR; ‡Arizona Cancer Center and Mel and Enid Zuckerman College of Public Health, Tucson, AZ; §Louisiana State University Health Sciences Center, New Orleans, LA; and ¶H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida

The authors thank the staff members of the University of Arizona Health Research Clinic, Tucson; the Men’s Research Clinic at Lifetime Cancer Screening and Prevention Center, H. Lee Moffitt Cancer Center, Tampa; and the Pima County Theresa Lee Health Center, Tucson. The authors are also grateful to Digene Corporation (Gaithersburg, MD) for donating reagents and supplies. The authors would also like to thank Maya Sternberg for assistance with data analysis, Katherine Stone for the assistance with the concept and study design, and Jim Braxton for assistance with data analysis.

Supported by the Centers for Disease Control and Prevention through the Association of American Medical Colleges, grants U36/CCU319276, AAMC ID number MM-0579–03/03. Publication and report contents are solely the responsibility of the authors and do not necessarily represent the official views of the AAMC or the CDC.

Correspondence: Eileen F. Dunne, MD, 1600 Clifton Rd, MS E-02, Atlanta, GA 30030. E-mail: dde9@cdc.gov.

Received for publication January 29, 2009, and accepted May 5, 2009.

© Copyright 2009 American Sexually Transmitted Diseases Association